Evidence map›Paper›PMID 32180150›Full record

Trial reportChinese journal of integrative medicine2020

Clinical Experience in Treatment of Alzheimer's Disease with Jiannao Yizhi Formula () and Routine Western Medicine.

Hui-Chan Wang, Nan-Yang Liu, Shuai Zhang, Yang Yang, Zhi-Yong Wang, Yun Wei, Jian-Gang Liu, Hui Pei, Hao Li

Abstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Chinese journal of integrative medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 3 pooled it
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 3 syntheses or guidelines pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Review
  6. Review
  7. Review
  8. Toxicological evaluation ofToxicology reports · 2024
    Article
  9. Review
  10. Review
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Hui-Chan WangGraduate School, Beijing University of Chinese Medicine, Beijing, 100029, China.
Nan-Yang LiuDepartment of Geratology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, 100091, China.
Shuai ZhangDepartment of Geratology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, 100091, China.
Yang YangDepartment of Geratology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, 100091, China.
Zhi-Yong WangDepartment of Geratology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, 100091, China.
Yun WeiDepartment of Geratology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, 100091, China.
Jian-Gang LiuDepartment of Geratology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, 100091, China.
Hui PeiDepartment of Geratology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, 100091, China.
Hao LiDepartment of Geratology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, 100091, China. xyhplihao1965@126.com.
Xiyuan Hospital · CNChinese Academy of Medical Sciences & Peking Union Medical College · CNBeijing University of Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo investigate the long-term therapeutic effects of the Chinese medicine Jiannao Yizhi Formula (, JYF) in the treatment of Alzheimer's disease (AD).

methodsSixty mild-to-moderate AD participants were recruited and randomly allocated to the treatment (30 with JYF) and the control groups (30 with donepezil) for 6 months with the random numbers. The primary outcomes were scores of Alzheimer's Disease Rating Scale-Cognitive (ADAS-Cog) and Chinese Medicine Symptom Scale (CM-SS). The secondary outcomes were scores of Mini Mental State Examination (MMSE), Montreal Cognitive Assessment (MoCA), and Activities of Daily Living (ADL). Safety assessments were conducted at baseline and the 6th month of treatment. Serum levels of acetylcholine (Ach), amyloid-β protein 42 (Aβ

resultsFifty-one participants were included in the final analyses (JYF n=27; donepezil n=24). Compared with baseline, both JYF and donepezil increased the MoCA and MMSE scores and decreased the ADAS-Cog and CM-SS scores (P<0.05 or P<0.01). Both drugs increased the serum levels of Ach and decreased the serum levels of Aβ

conclusionThe effect and safety of JYF for the treatment of AD were not inferior to those of donepezil.

Indexed as

Medicine, Chinese TraditionalAgedAged, 80 and overAlpiniaAlzheimer DiseaseAttentionBiomarkersCholinesterase InhibitorsCognitionDonepezilDrugs, Chinese HerbalExecutive FunctionFemaleHumansMaleMemoryAlpinia oxyphylla fruit extractBiomarkersCholinesterase InhibitorsDonepezilDrugs, Chinese HerbalPlant ExtractsAlzheimer’s diseaseChinese medicineclinical observasionJiannao Yizhi Formula

Identifiers

PMID32180150
OpenAlexW3011707564

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.